Codex DNA, Inc., creators of the BioXp system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, announced the release of a mRNA workflow for the BioXp workstation allowing scientists to generate synthetic mRNA from a DNA sequence in a single overnight run.
The building of mRNA has emerged as a highly attractive system for the development of both therapeutics and vaccines, with hundreds of such projects currently in various stages of development. Codex DNA’s new BioXp small-scale mRNA synthesis kit helps to alleviate many bottlenecks, as it contains all the Gibson Assembly reagents necessary to make micrograms of biologically active synthetic mRNA using de novo synthesized, error-corrected gene fragments (mRNA template) in a single overnight run.
The building of mRNA has emerged as a highly attractive system for the development of both therapeutics and vaccines, with hundreds of such projects currently in various stages of development. Codex DNA’s new BioXp small-scale mRNA synthesis kit helps to alleviate many bottlenecks, as it contains all the Gibson Assembly reagents necessary to make micrograms of biologically active synthetic mRNA using de novo synthesized, error-corrected gene fragments (mRNA template) in a single overnight run.
This solution is designed to offer the following benefits:
- On-demand synthesis of custom, biologically active mRNA ready for direct use in downstream workflows
- Format flexibility across DNA and mRNA applications
- Faster and scalable mRNA guided workflow
- Ability to construct genes, mRNA, and clones across a wide range of sizes and complexity
- Optimized for speed, predictability, and reproducibility of the synthetic biology design-build-test process
In addition, Codex DNA also added longer fragment cloning capabilities that enable scientists to produce error-corrected, multivariant, de novo synthetic genes up to 7.2 kilobase pairs (kb) in length, and clone them into custom vectors hands-free and overnight, using the company’s Gibson Assembly technology.
Given that the average protein size in humans is around 400 amino acids, the ability to synthesize genes up to 7.2kb in length means that the BioXp can enable researchers to study proteins roughly 6 times the size of the average human protein. Such improvement in size dramatically expands the menu of applications that can be studied, such as antibody engineering, metabolic engineering, small genome construction, targeted gene variant analysis, and more. Examples include the expression of critical molecules like monoclonal antibodies, nucleic acid-based vaccine sequences, and the SARS-CoV-2 spike protein.
Visit Codex DNA for more news.
